Among the enriched kinases associated with DAV sensitivity, CDK2, an inhibitor that has been widely employed to combat drug resistance in AML,[17, 36, 37] emerges as another potential predictor worthy of further discussion regarding its potential contribution to DA resistance, which may be overcome by DAV treatment. The gene discussed is CDK2; the disease is acute myeloid leukemia.